News & Events
Published On: 8/2/2017
TARGET PharmaSolutions Enrolls First Participant in its Inflammatory Bowel Disease (IBD) Community
CHAPEL HILL, NC – (August 2, 2017) – TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce enrollment of the first participant in its Inflammatory Bowel Disease community, TARGET-IBD, which includes adult and pediatric patients with ulcerative colitis, Crohn’s disease and indeterminate colitis.
TARGET-IBD is led by an academic steering committee chaired by Bruce Sands, MD (Mount Sinai), David Rubin, MD (University of Chicago), and Millie Long, MD (University of North Carolina). Dr. Bruce Sands noted that “We are excited to achieve this significant milestone and to advance the critical work of TARGET-IBD. By following both adult and pediatric populations in the real-world setting, this study provides an invaluable opportunity to enhance understanding of the natural disease course of IBD and, ultimately, to evaluate treatment regimens within different patient subsets.”
TARGET-IBD’s first participant enrolled on July 24th, 2017. TARGET-IBD will collect retrospective and prospective data on its enrolled patients and will develop a biorepository which its stakeholders can access for translational studies of viral resistance, genomics, and biomarkers. TARGET-IBD will enroll up to 15,000 patients at up to 100 sites over the next few years.
TARGET PharmaSolutions provides insights and actions to improve clinical, medical, and commercial outcomes throughout the pharmaceutical development and commercialization process. The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes. This model enables TARGET’s stakeholders to answer critical strategic and planning questions and to fulfill regulatory and payer requests. The TARGET model also provides its stakeholders access to a biorepository linked to validated clinical outcomes, including patient reported outcomes (PROs).
TARGET PharmaSolutions was formed in February, 2015 and has four disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), and TARGET-IBD (inflammatory bowel disease). The TARGET model is based on the success of HCV-TARGET, a case study in Hepatitis C. Formed in 2011 by Drs. Michael Fried, MD (University of North Carolina) and David Nelson, MD (University of Florida), HCV-TARGET has enrolled over 11,000 patients and has generated data that has been used by physicians, payers, and regulatory agencies around the world.
About Target RWE
Headquartered in Durham, NC, Target RWE is an innovative health evidence solutions company generating real-world evidence (RWE) and delivering regulatory-grade data to partners to advance clinical, medical, and commercial outcomes as well as to improve patient health guidelines and quality of care.
Target RWE has developed a turnkey health evidence solution which rapidly aggregates real-world data (RWD) from a large network of participating sites (academic and community) across the United States, Europe and other non-U.S. locations. Target RWE’s datasets are aggregated from various data sources including registries, electronic medical records, patient outcomes measures, biospecimen analyses, and claims databases. Whether partners need consulting services, datasets, support for custom solutions or access to a large biorepository of disease agnostic patient samples, Target RWE strives to be the preferred choice.
For more information, visit www.targetrwe.com.
984.234.0268 ext 205
05/07/2020Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
04/14/2020TARGET-NASH Observational Study Reaches 5,000 Enrolled Patients
03/17/2020TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships
03/13/2020TARGET PharmaSolutions Launches Real-World Asthma Study